TIOMAX: A Spanish Multicenter Registry of the real–world use of the TItanium OptiMAX® biostent: TIOMAX: Registro Español Multicéntrico Del Biostent De Titanio OptiMAX® En La Vida Real

Objectives To compare the safety and efficacy of the new cobalt‐chromium bioactive stent Titan Optimax® (Hexacath, France) with its predecessor, Titan‐2®. Background The TIOMAX registry includes 784 patients who underwent percutaneous coronary intervention with these stents in 21 Spanish hospitals....

Full description

Saved in:
Bibliographic Details
Published in:Catheterization and cardiovascular interventions 2018-08, Vol.92 (2), p.261-268
Main Authors: López‐Mínguez, José R., Nogales‐Asensio, Juan M., Romani, Sebastián, Rivero‐Crespo, Fernando, Aragón‐Extremera, Victor M., Jiménez‐Mazuecos, Jesús M., Carrasco, Fernando, Oteo‐Domínguez, Juan Francisco, Bosa‐Ojeda, Francisco, Gómez‐Hospital, Joan A.
Format: Article
Language:English
Subjects:
acute coronary syndrome with ST elevation
Acute coronary syndromes
Angina
bioactive titanium nitride oxide stent
Chromium
Cobalt
cobalt‐chromium bioactive stent
Death
Implants
Ischemia
Myocardial infarction
stent thrombosis
Stents
Thromboembolism
Thrombosis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To compare the safety and efficacy of the new cobalt‐chromium bioactive stent Titan Optimax® (Hexacath, France) with its predecessor, Titan‐2®. Background The TIOMAX registry includes 784 patients who underwent percutaneous coronary intervention with these stents in 21 Spanish hospitals. Methods Analysis of all patients in the registry without exclusion criteria, candidates for revascularization (March‐2013/July‐2014). Initially 273 patients received Titan‐2®, and the next 511 received the Optimax® after its launch. Results Mean age was 65.8 ± 13.0 (78.1% men); 49.2% were STEACS patients (n = 322), 29.8% NSTEACS, and 27.3% had stable angina or silent ischemia. Most STEACS patients (76.4% of n = 322) were treated
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.27326